141 related articles for article (PubMed ID: 32468814)
1. Biocatalytic Production of a Potent Inhibitor of Adipocyte Differentiation from Phloretin Using Engineered CYP102A1.
Nguyen NA; Jang J; Le TK; Nguyen THH; Woo SM; Yoo SK; Lee YJ; Park KD; Yeom SJ; Kim GJ; Kang HS; Yun CH
J Agric Food Chem; 2020 Jun; 68(24):6683-6691. PubMed ID: 32468814
[TBL] [Abstract][Full Text] [Related]
2. Enzymatic Production of 3-OH Phlorizin, a Possible Bioactive Polyphenol from Apples, by
Nguyen NA; Cao NT; Nguyen THH; Ji JH; Cha GS; Kang HS; Yun CH
Antioxidants (Basel); 2021 Aug; 10(8):. PubMed ID: 34439575
[TBL] [Abstract][Full Text] [Related]
3. Highly regioselective hydroxylation of polydatin, a resveratrol glucoside, for one-step synthesis of astringin, a piceatannol glucoside, by P450 BM3.
Le TK; Jang HH; Nguyen HT; Doan TT; Lee GY; Park KD; Ahn T; Joung YH; Kang HS; Yun CH
Enzyme Microb Technol; 2017 Feb; 97():34-42. PubMed ID: 28010771
[TBL] [Abstract][Full Text] [Related]
4. Regioselective hydroxylation of 17β-estradiol by mutants of CYP102A1 from Bacillus megaterium.
Cha GS; Ryu SH; Ahn T; Yun CH
Biotechnol Lett; 2014 Dec; 36(12):2501-6. PubMed ID: 25129047
[TBL] [Abstract][Full Text] [Related]
5. Plasma-induced dimerization of phloridzin as a new class of anti-adipogenic agents.
Jeong GH; Cho JH; Kim SH; Kim TH
Bioorg Med Chem Lett; 2017 Nov; 27(21):4889-4892. PubMed ID: 28958622
[TBL] [Abstract][Full Text] [Related]
6. Engineering bacterial cytochrome P450 (P450) BM3 into a prototype with human P450 enzyme activity using indigo formation.
Park SH; Kim DH; Kim D; Kim DH; Jung HC; Pan JG; Ahn T; Kim D; Yun CH
Drug Metab Dispos; 2010 May; 38(5):732-9. PubMed ID: 20100815
[TBL] [Abstract][Full Text] [Related]
7. Phloretin and phlorizin promote lipolysis and inhibit inflammation in mouse 3T3-L1 cells and in macrophage-adipocyte co-cultures.
Huang WC; Chang WT; Wu SJ; Xu PY; Ting NC; Liou CJ
Mol Nutr Food Res; 2013 Oct; 57(10):1803-13. PubMed ID: 23776070
[TBL] [Abstract][Full Text] [Related]
8. Role of residue 87 in substrate selectivity and regioselectivity of drug-metabolizing cytochrome P450 CYP102A1 M11.
Vottero E; Rea V; Lastdrager J; Honing M; Vermeulen NP; Commandeur JN
J Biol Inorg Chem; 2011 Aug; 16(6):899-912. PubMed ID: 21567268
[TBL] [Abstract][Full Text] [Related]
9. Application of engineered cytochrome P450 mutants as biocatalysts for the synthesis of benzylic and aromatic metabolites of fenamic acid NSAIDs.
Venkataraman H; Verkade-Vreeker MC; Capoferri L; Geerke DP; Vermeulen NP; Commandeur JN
Bioorg Med Chem; 2014 Oct; 22(20):5613-20. PubMed ID: 24999003
[TBL] [Abstract][Full Text] [Related]
10. An efficient route to selective bio-oxidation catalysts: an iterative approach comprising modeling, diversification, and screening, based on CYP102A1.
Seifert A; Antonovici M; Hauer B; Pleiss J
Chembiochem; 2011 Jun; 12(9):1346-51. PubMed ID: 21591046
[TBL] [Abstract][Full Text] [Related]
11. Hydroxylation of non-substituted polycyclic aromatic hydrocarbons by cytochrome P450 BM3 engineered by directed evolution.
Sideri A; Goyal A; Di Nardo G; Tsotsou GE; Gilardi G
J Inorg Biochem; 2013 Mar; 120():1-7. PubMed ID: 23262457
[TBL] [Abstract][Full Text] [Related]
12. Improving the activity of cytochrome P450 BM-3 catalyzing indole hydroxylation by directed evolution.
Pengpai Z; Sheng H; Lehe M; Yinlin L; Zhihua J; Guixiang H
Appl Biochem Biotechnol; 2013 Sep; 171(1):93-103. PubMed ID: 23817788
[TBL] [Abstract][Full Text] [Related]
13. Expanding the applicability of cytochrome P450s and other haemoproteins.
Ariyasu S; Stanfield JK; Aiba Y; Shoji O
Curr Opin Chem Biol; 2020 Dec; 59():155-163. PubMed ID: 32781431
[TBL] [Abstract][Full Text] [Related]
14. Altering the regioselectivity of the subterminal fatty acid hydroxylase P450 BM-3 towards gamma- and delta-positions.
Dietrich M; Do TA; Schmid RD; Pleiss J; Urlacher VB
J Biotechnol; 2009 Jan; 139(1):115-7. PubMed ID: 18984016
[TBL] [Abstract][Full Text] [Related]
15. Generation of human metabolites of 7-ethoxycoumarin by bacterial cytochrome P450 BM3.
Kim DH; Kim KH; Kim DH; Liu KH; Jung HC; Pan JG; Yun CH
Drug Metab Dispos; 2008 Nov; 36(11):2166-70. PubMed ID: 18669587
[TBL] [Abstract][Full Text] [Related]
16. Generation of human chiral metabolites of simvastatin and lovastatin by bacterial CYP102A1 mutants.
Kim KH; Kang JY; Kim DH; Park SH; Park SH; Kim D; Park KD; Lee YJ; Jung HC; Pan JG; Ahn T; Yun CH
Drug Metab Dispos; 2011 Jan; 39(1):140-50. PubMed ID: 20962060
[TBL] [Abstract][Full Text] [Related]
17. Regioselective hydroxylation of omeprazole enantiomers by bacterial CYP102A1 mutants.
Ryu SH; Park BY; Kim SY; Park SH; Jung HJ; Park M; Park KD; Ahn T; Kang HS; Yun CH
Drug Metab Dispos; 2014 Sep; 42(9):1493-7. PubMed ID: 25008345
[TBL] [Abstract][Full Text] [Related]
18. Regioselective Hydroxylation of Phloretin, a Bioactive Compound from Apples, by Human Cytochrome P450 Enzymes.
Nguyen NA; Cao NT; Nguyen THH; Le TK; Cha GS; Choi SK; Pan JG; Yeom SJ; Kang HS; Yun CH
Pharmaceuticals (Basel); 2020 Oct; 13(11):. PubMed ID: 33105851
[TBL] [Abstract][Full Text] [Related]
19. Scanning chimeragenesis: the approach used to change the substrate selectivity of fatty acid monooxygenase CYP102A1 to that of terpene omega-hydroxylase CYP4C7.
Chen CK; Berry RE; Shokhireva TKh; Murataliev MB; Zhang H; Walker FA
J Biol Inorg Chem; 2010 Feb; 15(2):159-74. PubMed ID: 19727859
[TBL] [Abstract][Full Text] [Related]
20. P450(BM3) on steroids: the Swiss Army knife P450 enzyme just gets better.
Wong LL
Chembiochem; 2011 Nov; 12(17):2537-9. PubMed ID: 21998091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
